TICKERNERD
Menu
SYRESYREHealthcare · Biotechnology

SYRE Stock Forecast: Spyre Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$104
+1.75% on the day

The 17 Wall Street analysts covering Spyre Therapeutics, Inc. hold a median 12-month price target of $127 — +22.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 46 of 100 as at 14 Aug 2026 — in the lower half.

Market cap
$9.0B
Ticker Nerd rank
46 / 100
Median analyst target
$127
Analysts covering
17
Total return, dividends reinvested
1W
−1.2%
1M
+4.7%
YTD
+216.3%
1Y
+514.7%
From 52W high
−1.6%
From 52W low
+599.3%
$15
$105
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SYRE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Spyre Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Aug 2026
46 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
99
Value
80
Quality
72
Revisions
52
Growth
48
Volatility
35
Issuance
28
Size
17
Accruals
16

Momentum (99): The shares have been drifting up relative to others.

Accruals (16): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SYRE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SYRE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$50$100$150Oct 25Jan 26Apr 26Jul 26SYREHigh $140Median $127Low $97

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says17 analysts
16 Buy1 Hold0 Sell
Low $97Median $127High $140

The green dot is the last close — the median target sits +22.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
11 Aug 2026BTIGMaintainsBuy$112 → $132
5 Aug 2026GuggenheimMaintainsBuy$115 → $130
5 Aug 2026WedbushMaintainsOutperform$100 → $130
5 Aug 2026Wells FargoMaintainsOverweight$90 → $115
28 July 2026Wolfe ResearchDowngradePeer Perform—
28 July 2026Wolfe ResearchDowngradePeer Perform—
13 July 2026MizuhoMaintainsOutperform—
13 July 2026MizuhoMaintainsOutperform$84 → $120
23 June 2026Deutsche BankMaintainsBuy—
15 June 2026BTIGMaintainsBuy—
4 June 2026Deutsche BankMaintainsBuy—
6 May 2026CitigroupMaintainsBuy—
6 May 2026StifelMaintainsBuy—
17 Apr 2026Jones TradingMaintainsBuy—
14 Apr 2026BairdMaintainsOutperform—
14 Apr 2026Deutsche BankMaintainsBuy—
14 Apr 2026Raymond JamesInitiatesStrong Buy—
14 Apr 2026WedbushMaintainsOutperform—
14 Apr 2026Wells FargoMaintainsOverweight—
13 Apr 2026BTIGMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SYRE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

SYRE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Spyre Therapeutics, Inc. (SYRE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
1.7×

Cheaper than 70% of US stocks

Price / sales
—
Price / book
9.4×

Cheaper than 11% of US stocks

EV / EBITDA
−35.6×

Cheaper than 92% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 33% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−23.0%

Higher than 30% of US stocks

Return on assets
−19.8%

Higher than 20% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

SYRE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SYRESpyre Therapeutics, Inc.$9.0B
46
IONSIonis Pharmaceuticals, Inc.$9.1B
47
CRNXCrinetics Pharmaceuticals, Inc.$8.7B
75
IMVTImmunovant, Inc.$8.4B
40
PCVXVaxcyte, Inc.$8.2B
49
KYMRKymera Therapeutics, Inc.$9.8B
74
KRYSKrystal Biotech, Inc.$9.8B
78

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Spyre Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SYRE news & analysis

Spyre Therapeutics Announces Grants of Inducement Awards

GlobeNewsWire · 7 Aug 2026neutral

Spyre Therapeutics announced that its Compensation Committee approved equity inducement awards, comprising stock options for 19,436 shares and 6,186 restricted stock units, granted to four non-executive employees under the company's 2018 Equity Inducement Plan. The awards, approved on August 3, 2026, were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters — The inducement awards signal Spyre's efforts to attract and retain talent as a clinical-stage biotechnology company, which SYRE watchers would follow as part of the company's ongoing operations.

SYRE's Q2 Loss Narrower Than Expected, Pipeline Progresses

Zacks Investment Research · 5 Aug 2026positive

Spyre Therapeutics reported a narrower-than-expected Q2 loss, while its pipeline showed positive phase II progress with upcoming data readouts on the horizon.

Why it matters — A narrower loss and advancing pipeline milestones could signal growing operational and clinical momentum for Spyre.

Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewsWire · 4 Aug 2026positive

Spyre Therapeutics reported second quarter 2026 financial results and provided a corporate update, announcing positive topline induction data for SPY001 and SPY002 from Part A of the Phase 2 SKYLINE trial. The data demonstrated best-in-class efficacy potential and a safety profile consistent with in-class comparators.

Why it matters — A SYRE watcher would care because positive Phase 2 SKYLINE topline results for two lead candidates signal progress in the company's clinical pipeline.

FAQ

Frequently asked questions about SYRE stock

What is the SYRE stock price forecast for 2026-2027?

The 17 Wall Street analysts covering Spyre Therapeutics, Inc. have a median 12-month price target of $127, with estimates ranging from $97 to $140. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SYRE stock a buy right now?

Of the 17 analysts covering Spyre Therapeutics, Inc., 16 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Spyre Therapeutics, Inc. 46 out of 100 across roughly 4,600 US stocks as at 14 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SYRE?

As at 14 Aug 2026, Spyre Therapeutics, Inc. ranks 46 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).

Will SYRE stock go up?

No one can know that. What the data says: the median 12-month target from 17 analysts implies +22.1% from the last close, and Ticker Nerd's factor model ranks Spyre Therapeutics, Inc. 46 out of 100 as at 14 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SYRE stock forecast for 2030?

No analyst covering Spyre Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SYRE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $97 to $140 over the next 12 months.

How has SYRE stock performed over the past year?

Spyre Therapeutics, Inc. returned +514.7% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Spyre Therapeutics, Inc. do?

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company developing next-generation antibodies engineered for prolonged activity in the body, formulated for delivery as monotherapies or combination therapies.

What is the latest news on SYRE?

The most recent item we track (GlobeNewsWire, 7 Aug 2026): "Spyre Therapeutics Announces Grants of Inducement Awards". Spyre Therapeutics announced that its Compensation Committee approved equity inducement awards, comprising stock options for 19,436 shares and 6,186 restricted stock units, granted to four non-executive employees under the company's 2018 Equity Inducement Plan. The awards, approved on August 3, 2026, were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).

Company

About Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company developing next-generation antibodies engineered for prolonged activity in the body, formulated for delivery as monotherapies or combination therapies. These innovative antibodies target validated mechanisms to address inflammatory bowel disease (IBD) such as ulcerative colitis, as well as other immune-mediated diseases including gastrointestinal and rheumatic conditions. The company's pipeline includes programs like SPY001, currently in clinical trials such as the SKYLINE trial evaluating induction results in moderate-to-severe ulcerative colitis patients. Spyre Therapeutics focuses on creating disruptive solutions that offer potential improvements in efficacy and convenience for patients and caregivers dealing with high-burden immune-mediated disorders. Founded in 2013 and headquartered in Waltham, Massachusetts, Spyre Therapeutics plays a key role in advancing biotechnology innovations for underserved therapeutic areas in immunology.

CEO Dr. Cameron Turtle DPHIL, Ph.D. · 125 employees · United States · https://www.spyre.com